These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 20505644)

  • 1. Pazopanib in renal cell carcinoma.
    Sternberg CN
    Clin Adv Hematol Oncol; 2010 Apr; 8(4):232-3. PubMed ID: 20505644
    [No Abstract]   [Full Text] [Related]  

  • 2. Everolimus and pazopanib: two new drugs for renal cell cancer.
    Med Lett Drugs Ther; 2010 May; 52(1337):33-4. PubMed ID: 20431519
    [No Abstract]   [Full Text] [Related]  

  • 3. Nursing considerations for patients receiving pazopanib for renal cell carcinoma.
    Becze E
    ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508
    [No Abstract]   [Full Text] [Related]  

  • 4. Pazopanib, a potent orally administered small-molecule multitargeted tyrosine kinase inhibitor for renal cell carcinoma.
    Sonpavde G; Hutson TE; Sternberg CN
    Expert Opin Investig Drugs; 2008 Feb; 17(2):253-61. PubMed ID: 18230058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pazopanib: therapeutic developments.
    Limvorasak S; Posadas EM
    Expert Opin Pharmacother; 2009 Dec; 10(18):3091-102. PubMed ID: 19954277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report.
    Matrana MR; Ng C; Rao P; Lim ZD; Tannir NM
    Clin Genitourin Cancer; 2011 Dec; 9(2):137-9. PubMed ID: 21831725
    [No Abstract]   [Full Text] [Related]  

  • 7. The European Medicines Agency review of pazopanib for the treatment of advanced renal cell carcinoma: summary of the scientific assessment of the Committee for Medicinal Products for Human Use.
    Nieto M; Borregaard J; Ersbøll J; ten Bosch GJ; van Zwieten-Boot B; Abadie E; Schellens JH; Pignatti F
    Clin Cancer Res; 2011 Nov; 17(21):6608-14. PubMed ID: 21976546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib in renal cell carcinoma.
    Ward JE; Stadler WM
    Clin Cancer Res; 2010 Dec; 16(24):5923-7. PubMed ID: 21059813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pazopanib.
    Bukowski RM; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2010 Jan; 9(1):17-8. PubMed ID: 20043026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma.
    Bourdeanu L; Twardowski P; Pal SK
    Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged survival of a patient with papillary renal cell carcinoma and brain metastases using pazopanib.
    Jacobs C; Kim DW; Straka C; Timmerman RD; Brugarolas J
    J Clin Oncol; 2013 Mar; 31(7):e114-7. PubMed ID: 23319695
    [No Abstract]   [Full Text] [Related]  

  • 12. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma.
    Zivi A; Cerbone L; Recine F; Sternberg CN
    Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological sheet: pazopanib (Votrient), oral administration].
    J Pharm Belg; 2011 Sep; (3):95-6. PubMed ID: 21995103
    [No Abstract]   [Full Text] [Related]  

  • 14. Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma.
    Asaithambi G; Peters BR; Hurliman E; Moran BP; Khan AS; Taylor RA
    J Clin Pharm Ther; 2013 Apr; 38(2):175-6. PubMed ID: 23210935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients?
    Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pazopanib (Votrient) in the management of renal cell cancer and soft tissue sarcomas].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2012; 67(7-8):437-42. PubMed ID: 22984765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Pazopanib for treatment of renal cell carcinoma and soft tissue sarcomas].
    Brotelle T; Bay JO
    Bull Cancer; 2014 Jun; 101(6):641-6. PubMed ID: 24977453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NICE guidance on pazopanib for first-line treatment of advanced renal-cell carcinoma.
    Griffiths C; Hay N; Sutcliffe F; Stevens A
    Lancet Oncol; 2011 Mar; 12(3):221-2. PubMed ID: 21495242
    [No Abstract]   [Full Text] [Related]  

  • 19. [Adjuvant AUO study of renal cell carcinoma after nephrectomy: randomized, double-blind, placebo-controlled phase III study (PROTECT - AN 30/10) to investigate the effectiveness and safety of pazopanib as adjuvant therapy in patients with localized or local advanced renal cell carcinoma after nephrectomy].
    Rexer H
    Urologe A; 2011 Apr; 50(4):489-92. PubMed ID: 21472622
    [No Abstract]   [Full Text] [Related]  

  • 20. Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.
    Cella D; Pickard AS; Duh MS; Guerin A; Mishagina N; Antràs L; Neary MP; McCann L; Hodge R; Sternberg CN
    Eur J Cancer; 2012 Feb; 48(3):311-23. PubMed ID: 21689927
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.